Maintenance treatment with MGN1703 following standard first-line treatment prolongs progression-free survival in patients with metastatic colorectal cancer

MGN1703 is a synthetic DNA-based immunomodulator with TLR-9 agonist activity. The results of the study on maintenance therapy with MGN1703 following successful standard first-line treatment in patients with metastatic colorectal cancer (mCRC) were reported by Dr Dirk Arnold at the proffered papers session of the Gastrointestinal, Colorectal Cancer program track of the ESMO 2012 Congress in Vienna. Read more here.